76866-73-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(dimethylamino)ethyl diethylcarbamate is used as an anti-parasitic agent for the treatment of infections caused by filarial worms and some roundworms. It is particularly effective in combating lymphatic filariasis and onchocerciasis, providing a crucial therapeutic intervention for individuals affected by these parasitic diseases.
Used in Public Health Initiatives:
In the context of public health, 2-(dimethylamino)ethyl diethylcarbamate serves as a key component in mass drug administration programs aimed at controlling and eliminating lymphatic filariasis and onchocerciasis. Its role in these initiatives is vital for reducing the prevalence of these diseases and improving the overall health of affected populations.
Used in Veterinary Medicine:
Although primarily used in human medicine, 2-(dimethylamino)ethyl diethylcarbamate may also find application in veterinary medicine for the treatment of parasitic infections in animals, contributing to the overall health and well-being of pets and livestock.

Upstream product

• 108-01-0 2-(N,N-dimethylamino)ethanol 
• 88-10-8 N,N-diethylcarbamyl chloride 

Relevant academic research and scientific papers

Analogues of carbacholine: Synthesis and relationship between structure and affinity for muscarinic and nicotinic acetylcholine receptors

A series of acyclic and heterocyclic analogues of carbacholine (1) was synthesized using N-methylcarbacholine (MCC, 2), N,N-dimethylcarbacholine (DMCC, 3), and the corresponding tertiary amine (4) as leads. Whereas nicotinic acetylcholine receptor affinity was determined using [3H]nicotine as the radioactive ligand, [3H]oxotremorine-M ([3H]Oxo-M) and [3H]quinuclidinyl benzilate ([3H]QNB), in some cases supplemented with [3H]pirenzepine ([3H]PZ), were used as radioligands for muscarinic acetylcholine receptors on rat brain membranes. On the basis of receptor binding data, nicotinic/muscarinic (N/M) selectivity factors were determined, and muscarinic receptor efficacy (M agonist index) and M1 selectivity (M2/M1 index) estimated. In most cases, quaternized analogues showed higher affinity than the corresponding tertiary amines for muscarinic and, in particular, nicotinic receptor sites. Among the new compounds, N,N-diethylcarbacholine (9e) (IC50 = 0.046 μM), (S)-1-methyl-2-(N,N-dimethylaminocarbonyloxymethyl)pyrrolidine (17k) (IC50 = 0.068 μM), and the corresponding quaternized analogue, 18k (IC50 = 0.018 μM) showed the highest nicotinic receptor affinity. The tertiary amine, 17k showed much higher nicotinic receptor affinity than the acyclic analogue, 4 (IC50 = 5.7 μM), and the N/M selectivity factor determined for 17k (150) is an order of magnitude lower than that of nicotine (1400). The N/M selectivity factors for MCC (2) and DMCC (3), previously reported to be highly selective nicotinic receptor ligands, were shown to be 6.5 and 60, respectively, the latter value being comparable with that of 18k (89).